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Abstract 
Background: MicroRNAs (miRNAs) regulate gene expression in physiological as well as in 
pathological processes, including chronic pain. Whether deletion of a gene can affect 
expression of the miRNAs that associate with the deleted gene mRNA remains elusive. We 
investigated the effects of brain-derived neurotrophic factor (Bdnf) gene deletion on the 
expression of miR-1 in dorsal root ganglion (DRG) neurons and its pain-associated 
downstream targets heat shock protein 60 (Hsp60) and connexin 43 (Cx43) in tamoxifen-
inducible conditional knockout mice, Bdnf
fl/fl
;Advillin-CreER
T2
 (Bdnf cKO). 
Results: Efficient Bdnf gene deletion was confirmed in DRG of Bdnf cKO mice by Real-
Time qRT-PCR and ELISA 10 days after completed tamoxifen treatment. In DRG, miR-1 
expression was reduced 0.44-fold (p < 0.05; Real-time qRT-PCR) in Bdnf cKO compared to 
floxed wildtype littermate control Bdnf
fl/fl
 mice (WT). While Hsp60 protein expression was 
increased 1.85-fold (p < 0.05; Western blot analysis), expression levels of Cx43 and the miR-
1-associated transcription factors MEF2a and SRF remained unchanged. When analyzing 
Bdnf cKO mice 32 days after complete tamoxifen treatment to investigate whether observed 
expression alterations remain permanently, we found no significant differences between Bdnf 
cKO and WT mice. However, miRNA microarray analysis revealed that 167 miRNAs altered 
(p < 0.05) in DRG of these mice following Bdnf gene deletion. 
Conclusions: Our results indicate that deletion of Bdnf in DRG neurons leads to a temporary 
dysregulation of miR-1, suggesting an impairment of a presumable feedback loop between 
BDNF protein and its targeting miR-1. This appears to affect its downstream protein Hsp60 
and as a consequence might influence the phenotype after inducible Bdnf gene deletion. While 
this appears to be a MEF2a-/SRF-independent and transient effect, expression levels of 
various other miRNAs may remain permanently altered. 
Keywords: microRNA, miR-1, Bdnf, gene deletion, BDNF-Advillin-Cre-ERT2, neuropathic 
pain, dorsal root ganglion  
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Background 
MicroRNAs (miRNAs) have attracted attention in basic pain research due to their 
dysregulation in chronic pain states (Elramah et al., 2014; Kress et al., 2013; Zhao et al., 
2010). This class of small non-coding RNA molecules modulates gene expression by 
posttranscriptional silencing of target mRNAs (Bartel, 2004). Differential expression of 
proteins and altered gene regulation may arise as a consequence of neuropathic pain  
(Costigan et al., 2009) which results from a lesion or dysfunction affecting the somatosensory 
system (Treede et al., 2008). To this day, for most individual miRNAs, their roles in specific 
gene regulation in the context of chronic pain remain elusive. 
Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin family  (Huang 
and Reichardt, 2003). The protein is critically involved in pathological nociceptive processes 
such as neuropathic pain (Coull et al., 2005). It has been demonstrated previously that 
microRNA-1 (miR-1) negatively regulates BDNF expression by directly targeting the 3` 
untranslated region (UTR) of Bdnf mRNA  (Brandenburger et al., 2014; Varendi et al., 2014). 
Important insights in understanding Bdnf gene function in nociception were provided by 
studies using various transgenic knockout mice  (MacQueen et al., 2001; Zhao et al., 2006). 
Whether gene deletion in transgenic mice in general has an impact on corresponding miRNAs 
is completely unknown. In this study we asked whether neuron-specific deletion of BDNF in 
DRG affects its interaction with miR-1.  
To address this question, we used DRG neuron-specific, tamoxifen-inducible adult Bdnf 
conditional knockout mice (Bdnffl/fl;Advillin-CreERT2) with an early (on day 10) and late (on 
day 32) time point after completion of tamoxifen induction treatment. This tissue-specific 
gene deletion was achieved by crossing Bdnffl/fl mice that carried a loxP-flanked Bdnf gene 
with Bdnffl/fl;Advillin-CreERT2 mice expressing the Cre recombinase driven by the promotor 
of Advillin gene, which is a peripheral sensory neuron-specific marker. It is important to note 
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that Advillin-CreER
T2
 transgenic mice showed no neuronal cell loss and displayed a normal 
phenotype in various pain models (Lau et al., 2011). We hypothesize a positive regulatory 
loop from BDNF protein towards miR-1 suggesting this feedback mechanism being altered in 
an inducible BDNF knockout mouse strain. Thus, we asked whether Bdnf gene deletion 
affects the positive feedback loop resulting in an altered miR-1 expression. In addition, there 
is evidence that miR-1 negatively regulates heat shock protein 60 (Hsp60) (Pan et al., 2012; 
Shan et al., 2010) and connexin 43 (Cx43) (Yang et al., 2007). Interestingly, both proteins are 
linked to neuropathic pain (Chen et al., 2012; Mor et al., 2011). Recently, we reported that 
neuropathic pain in rats with chronic-constriction injury is associated with reduced expression 
of miR-1 and increased levels of Cx43 protein in the injured sciatic nerve (Neumann et al., 
2015). Hsp60 was additionally reported to play an important role in neurodegeneration 
(Lehnardt et al., 2008) and was identified among a group of axonally synthesized proteins in 
cultures of injury-conditioned adult dorsal root ganglion (DRG) neurons (Willis et al., 2005). 
Consequently, we analyzed the expression of Hsp60 and Cx43 in Bdnf cKO mice. Finally, we 
investigated whether transcriptional regulation has an impact on miR-1 and Bdnf gene 
expression by analyzing the expression of serum response factor (SRF) and myocyte enhancer 
factor 2 (MEF2a). Both transcription factors have been described to regulate expression of 
miR-1 (Chen et al., 2006; Simon et al., 2008; Zhao et al., 2005). 
In this study, we focus on miR-1 and its interaction with BDNF suggesting their integration in 
a regulatory positive feedback mechanism. At an early time point after Bdnf gene deletion this 
positive regulatory loop seems to be interrupted resulting in a downregulation of miR-1. 
Hence, we decribe the impact of the suppressed miRNA expression on its downstream targets 
Hsp60 and Cx43, which are both associated with neuropathic pain. Finally, we study possible 
prolongation of changes in expression levels at a later time point after Bdnf gene deletion and 
provide additional information on further dysregulated miRNAs in these animals. 
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Results 
BDNF expression in Bdnf cKO mice at an early time point after BDNF gene deletion 
In the first experimental series, we investigated animals at an early time point after Bdnf gene 
deletion. Here, tissue was removed on day 10 after the last tamoxifen injection. To quantify 
Bdnf gene expression changes we performed real-time qRT-PCR on peripheral nerve, DRG 
and spinal cord tissue. Compared to tamoxifen treated floxed wildtype littermate control 
Bdnf
fl/fl
 mice (WT), Bdnf cKO mice showed a pronounced reduction of Bdnf mRNA in DRG 
(relative epression 0.31 vs. WT, p < 0.001), while in the sciatic nerve (relative expression 
0.74 vs. WT, p = 0.60) and spinal cord (relative expression 1.15 vs. WT, p = 0.14) no 
expression changes were detectable (Figure 1A-1C). Efficient Bdnf gene alteration on the 
protein level was confirmed by ELISA in DRG (338 ? 27 pg/mg in cKO vs. 518 ± 32 pg/mg 
in WT; p < 0.01) whereas BDNF protein expression in the peripheral nerve (187 ± 37 pg/mg 
in cKO vs. 230 ± 50 pg/mg in WT; p = 0.51) and spinal cord (398 ± 18 pg/mg in cKO vs. 424 
± 35 pg/mg in WT; p = 0.52) remained unchanged (Figure 1D-1F).  
 
miR-1 downregulation in DRG of Bdnf cKO mice at an early time point after Bdnf gene 
deletion 
We next assessed the potential effect on the interaction between miR-1 and BDNF by a 
hypothesized impaired positive feedback loop due to Bdnf gene deletion. We therefore 
analyzed the expression of miR-1 in DRG of Bdnf cKO mice on day 10 after completed 
tamoxifen treatment, which was downregulated to 0.44-fold (p < 0.05) compared to WT 
(Figure 2A). By contrast, miR-124a expression levels remained unchanged (0.74-fold vs. WT; 
p = 0.36) (Figure 2B). This microRNA has been reported not to interact with BDNF and thus 
served as a control. 
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Hsp60 and Cx43 expression in DRG of Bdnf cKO mice at an early time point after Bdnf 
gene deletion 
To address the impact of the downregulated miR-1 expression on its downstream targets we 
investigated the changes of protein levels of Hsp60 and Cx43. Being involved in nociceptive 
pathways, both proteins are known to be regulated by miR-1. Western blot analysis revealed a 
significantly elevated Hsp60 protein expression (1.85-fold; p < 0.05) in DRG of Bdnf cKO 
mice on day 10 after completed tamoxifen treatment compared to WT (Figure 3A). The 
protein level of Cx43 however was not significantly altered (0.76-fold vs. WT; p = 0.32) 
(Figure 3B).  
 
MEF2a and SRF expression in DRG of Bdnf cKO mice at an early time point after Bdnf 
gene deletion 
To study whether MEF2a and SRF contribute to the regulation of miR-1 and its interaction 
with BDNF we analyzed protein levels of both transcription factors. No significant changes 
could be determined in DRG of Bdnf cKO mice on day 10 after tamoxifen injection (relative 
SRF protein expression 0.99 vs. WT; p = 0.99; relative MEF2a protein expression 0.91 vs. 
WT; p = 0.48) (Supplemental Material 1). 
 
BDNF and miR-1 expression in DRG of Bdnf cKO mice at a late time point after Bdnf 
gene deletion 
To test whether the expression changes observed in the first set of experiments based on an 
early time point after Bdnf gene deletion are permanent, we next investigated animals at a 
later timepoint after Bdnf gene deletion. For this purpose, tissue was removed 32 days after 
the last tamoxifen treatment. Compared to WT controls, Bdnf cKO mutants showed a 
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significant reduction of Bdnf mRNA in DRG (relative expression 0.49 vs. WT; p < 0.05) 
(Figure 4).  
We next examined the expression level of miR-1 in DRG at the later stage after Bdnf gene 
deletion, which was 0.74-fold as compared with WT controls (p = 0.46) (Figure 5). 
 
Hsp60 and Cx43 expression in DRG of Bdnf cKO mice at a late time point after Bdnf 
gene deletion 
In line with the almost unchanged expression of miR-1, upregulation of Hsp60 protein 
expression (1.50-fold) did not reach significance (p = 0.08) 32 days after Bdnf gene deletion 
(Figure 6A). As observed at the early time point, Cx43 protein expression remained 
unchanged (0.96-fold in Bdnf cKO vs. WT; p = 0.94) (Figure 6B). 
 
Expression analysis of miRNAs in DRG of Bdnf cKO mice at a late time point after Bdnf 
gene deletion using microRNA microarray  
As described above, expression analyses did not show a significant regulation of miR-1, 
Hsp60 protein and Cx43 protein in Bdnf cKO mice at a late time point after Bdnf gene 
deletion. We extended our analysis to further investigate whether miRNA-associated effects 
are exclusive to Bdnf cKO mice at an early stage after Bdnf gene deletion. Using miRNA 
microarray analysis we detected a total of 167 significantly (p < 0.05) modified mature 
miRNAs in DRG of Bdnf cKO mice on day 32 after Bdnf gene deletion (Figure 7A) including 
54 miRNAs with an expression change of a minimum of 20% (Figure 7B). A fraction of 16 of 
these 54 miRNA alterations were found to be higly significant (p < 0.01). While the 
expression level of miR-1a-3p, which directly targets the 3` UTR of Bdnf mRNA, was not 
altered (relative expression 1.10 vs. WT; p = 0.55) the expression level of miR-1b-3p, which 
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is not known to be involved in BDNF regulation was reduced to 0.80-fold (p<0.01). 
Furthermore, we identified the bioinformatically predicted Cx43-linked miR-30f 
(www.targetscan.org), which was upregulated to 1.21-fold (p < 0.05).  
Discussion 
In this study we present essential effects of Bdnf gene deletion in DRG neurons on miRNAs, 
in particular on expression levels of miR-1 and its downstream targets. For this purpose we 
have employed DRG-specific and tamoxifen-inducible adult Bdnf cKO mice which yield an 
attractive approach to investigate BDNF function in pain pathways including neuropathic 
pain. These DRG-specific conditional BDNF-deficient mice were generated by crossing 
Bdnf
fl/fl 
mice with Advillin-CreER
T2
 mice expressing tamoxifen-inducible Cre recombinase 
driven by Advillin promotor. Importantly, the pain phenotype of the Advillin-CreER
T2
 mice 
was normal  (Lau et al., 2011). We showed that Bdnf gene deletion was restricted to DRG. 
Bdnf gene expression levels remained unchanged in sciatic nerve and spinal cord tissue. In 
line with these findings, Advillin gene expression studies by Northern blot analyses and in 
situ hybridization  (Marks et al., 1998) and further histological analyses  (Hasegawa et al., 
2007) revealed a strong expression and staining, respectively of the promotor in particular in 
DRG.  
Since Bdnf gene expression seems to be regulated by specific miRNAs loss of this 
neurotrophic factor prompts the question of unforeseen miRNA changes in ablation of Bdnf in 
the mutant mice. To address this issue, we focused on miR-1 which was previously detected 
in mouse DRG and localized in sensory neurons  (Bastian et al., 2011). Secondly, it has been 
reported that miR-1 is dysregulated in mouse DRG in different pain states  (Kusuda et al., 
2011). Thirdly, miR-1 negatively modulates Bdnf gene expression  (Brandenburger et al., 
2014; Varendi et al., 2014) and inhibits expression of the neuropathic pain-associated proteins 
Hsp60 and Cx43  (Pan et al., 2012; Shan et al., 2010; Yang et al., 2007). To regulate specific 
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genes, recent studies implicate that microRNAs even participate in feedback or feed forward 
mechanisms  (Tsang et al., 2007). Chen and colleagues identified a negative feedback model 
in which miR-1 is incorporated to control skeletal muscle gene expression  (Chen et al., 
2006). In terms of miR-1 and BDNF, we hypothesize a positive regulatory loop from BDNF 
towards miR-1 (Figure 8A) suggesting this feedback mechanism becoming interrupted with 
the loss of BDNF in Bdnf cKO mice (Figure 8B).  
In the present study, we first investigated animals at an early time point after Bdnf gene 
deletion (10 days after the last tamoxifen treatment) and found a remarkable downregulation 
of miR-1 in DRG compared to WT controls. The altered miR-1 expression may be a 
consequence of a disturbed positive regulatory loop in conditional Bdnf cKO mice. Given that 
transcriptional regulation processes are essential for gene activation, inhibition and expression 
including miRNA expression  (Guo et al., 2014; Hobert, 2008) we analyzed the 
transcriptional factors MEF2a and SRF. Feedback loops between MEF2/SRF and miR-1 have 
been described earlier  (Chen et al., 2006; Zhao et al., 2005) and both proteins are key 
regulators of neuronal differentiation and mediate growth factor-related functions  (Knöll and 
Nordheim, 2009; Lin et al., 1996). Nonetheless, MEF2a and SRF do not seem to be involved 
in controlling the interaction between miR-1 and BDNF in Bdnf cKO mice at an early time 
point after Bdnf gene deletion. However, we reasoned that the suppressed miR-1 might have 
an impact on its downstream targets Hsp60 and Cx43. Western blot analyses showed an 
almost twofold increase of Hsp60 expression in DRG of Bdnf cKO animals. The Hsp60 data 
indicate protein induction resulting from diminished posttranscriptional inhibition due to 
reduced expression of miR-1. In contrast to that finding, no Cx43 expression changes could 
be determined. It is tempting to speculate that the discrepancy between Hsp60 and Cx43 data 
may result from a more complex Cx43 gene structure and regulation  (Pfeifer et al., 2004). 
Not only the length of mouse Cx43 3` UTR is 1706 nucleotides, but there are 21 
bioinformatically predicted miRNA families, which are supposed to interact with Cx43 
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(www.targetscan.org), including miR-30f, which we found to be increased in DRG at the later 
timepoint after Bdnf gene deletion. By contrast, the length of mouse Hsp60 3` UTR is 
considerably shorter (462 nucleotides). In addition to the miR-1-3p/206/613 family, Hsp60 is 
predicted to be regulated by eleven other miRNA families conserved in all vertebrates 
(www.targetscan.org). However, from these only miR-140-3p was detected by the performed 
miRNA microarray to be affected with a reduced expression in DRG of Bdnf cKO animals 
(ratio 0.60; p < 0.01), a modification that may contribute to increased expression of Hsp60.  
Since the first set of experiments was based on an early time point after Bdnf gene targeting 
we asked whether the dysregulation of miR-1 and Hsp60 in DRG was permanent. Therefore, 
we analyzed Bdnf cKO mice 32 days after completion of tamoxifen injections. At this later 
time point only minor and non-significant alterations of miR-1 and Hsp60 were observed. 
Cx43 expression remained unmodified. However, these results can not rule out long-lasting 
miR dysregulation. To clarify whether miRNA dysregulations after Bdnf gene deletion are 
temporary and can therefore be generally prevented by investigating Bdnf cKO mice only at a 
later timepoint after induction of gene deletion, we performed a global miRNA microarray 
expression analysis. This analysis revealed a total of 167 significant differentially expressed 
miRNAs in Bdnf cKO mice on day 32 after completed tamoxifen injection providing two 
pieces of important information. Firstly, the bioinformatically predicted Cx43-associated mir-
30f miRNA was significantly upregulated to 1.2-fold. Secondly, microarray analyses revealed 
a large number of misexpressed miRNAs with other targets than BDNF, Hsp60 or Cx43. 
Hence, DRG-specific Bdnf gene deletion in Bdnf cKO mice does not lead to permanent 
dysregulation of the BDNF-targeting miRNA miR-1 and its other targets Hsp60 and Cx43 but 
seems to be sensitive to significant alteration of various other microRNAs.  
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Conclusion 
In summary, we found a significant downregulation of miR-1 in DRG 10 days after Bdnf gene 
deletion induced by tamoxifen treatment in Bdnf cKO mice, which appears to be MEF2a-
/SRF-independent, as well as an upregulation of the neuropathic pain-associated protein 
Hsp60. We presume a previously unkown feedback mechanism between a manipulated gene 
(Bdnf) and its regulating miRNA (miR-1) affecting its downstream target (Hsp60) in an early 
inducible Bdnf cKO. Here, the lack of a protein that serves essential functions in 
somatosensation may contribute to a specific miRNA-mediated abnormal pain phenotype. 
These miR-1-associated effects could not be confirmed in Bdnf cKO mice at a later timepoint 
after Bdnf gene deletion and thus may be transient, although permanent miR dysregulation 
cannot be excluded. Even at a later timepoint after Bdnf gene deletion, BDNF protein-
deficiency still appears to trigger misexpression of multiple other miRNAs. Given the 
importance of understanding Bdnf gene function in chronic pain conditions by using 
conditional BDNF knockout, miRNA-associated effects occuring irrespective of the specific 
targeted gene may be important to consider.   
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Methods 
Animals 
All tests were approved by the United Kingdom Home Office Animals (Scientific Procedures) 
Act 1986. Experiments were conducted using at least 6 weeks old mice of both sexes and 
identical genetic background (C57BL6/J). The same observer performed all experiments and 
was blind to the genotype of the animals.  
 
Generation of Bdnf cKO transgenic mice 
Transgenic Bdnf
fl/fl 
mice carrying loxP sites flanking the exons 5 in the Bdnf gene were 
interbred with Advillin-CreER
T2
 mice expressing a tamoxifen-inducible modified Cre 
recombinase under the control of the DRG neuron-specific advillin promoter (Lau et al., 
2011) to obtain Bdnf
fl/fl
;Advillin-CreER
T2
 mice. Genotyping of mice for Bdnf
fl/fl
 and Cre was 
performed by standard PCR as previously described (Lau et al., 2011; Zhao et al., 2006). 
Mice carrying Bdnf
fl/fl
 and Advillin-CreER
T2
 are referred to as ‘Bdnf cKO mice’, the 
respective Bdnf
fl/fl
;Cre-null mice are called ‘WT mice’, as they are phenotypically normal. To 
delete the Bdnf gene, the Bdnf cKO and WT control mice were treated with tamoxifen at the 
age of 8-12 weeks as described  (Lau et al., 2011). Mice were housed with a 12-hr light/dark 
cycle and maintained under standard condition (21 ± 1°C, food and water ad libitum). A five-
day treatment with tamoxifen (2 mg per day; intraperitoneal injection) induced a highly 
specific recombinase activity, which was confined to sensory neurons. The resulting 
transgenic mice were healthy with no sensory neuron loss. Animals with early and late BDNF 
gene targeting (10 days and 32 days after induction) and floxed BDNF control littermates 
were used for the present study.  
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RNA isolation 
Total RNA of sciatic nerve, dorsal root ganglia and spinal cord tissue was isolated using 
Trizol reagent (Invitrogen, Carlsbad, USA) according to the manufacturer`s protocol. RNA 
integrity was verified by Agilent microfluid chips using an Agilent 2100 Bioanalyzer 
(Agilent, USA). All samples in this study showed high quality RNA Integrity Numbers (RIN 
varied between 7.0 and 7.6). RNA was further analyzed by UV spectrophotometry 
(Nanodrop, Thermo Scientific, USA) and quantified by a fluorimetric Qubit RNA assay 
(Invitrogen). 
 
Microarray based microRNA expression analysis 
Biotin labeling of four biological replicates per genotype was performed according to the 
manufacturer´s protocol (FlashTag Biotin HSR RNA Labeling Kit, Affymetrix, Inc.). Briefly, 
250 ng of total RNA were ligated to biotin labeled DNA dendrimers after poly(A) tailing. 
Labeled RNA was hybridized to Affymetrix miRNA 4.0 Microarrays for 18h at 48 °C, 
stained by strepatavidin/phycoerythrin conjugate and scanned as described in the 
manufacturer´s protocol. Data analyses on Affymetrix CEL files were conducted with Partek 
Genomics Suite software (vers. 6.6; Partek, Inc.). Probes within each probeset were 
summarized by means of robust multi-array average algorithm after quantile normalization of 
probe level signal intensities across all samples to reduce inter-array variability  (Bolstad et 
al., 2003).  
 
Real-time Quantitative Reverse-transcripional Polymerase Chain Reaction of 
microRNAs 
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One μg of total RNA was reverse transcribed using the high capacity RNA-to-cDNA master 
mix (Applied Biosystems, USA). qPCR assays for mmu-miR-1 (Assay ID: 002222, Applied 
Biosystems), mmu-miR-124a (Assay ID: 001182, Applied Biosystems) and GAPDH (for 
normalization, Assay ID: 99999915_g1, Applied Biosystems) were used in accordance with 
the manufacturer’s instructions. qPCR conditions: 50°C for 2 min, 95°C for 10 min, 40 cycles 
of 95°C for 15 s, 60°C for 60 s on an Applied Biosystems 7300HT thermocycler (Applied 
Biosystems). All samples were run in triplicates (miRs) or duplicates (GAPDH). Relative 
expression was estimated using the ΔΔCt method {Pfaffl, 2001 #2584}. 
 
Protein isolation and Western blot analyses of Cx43, Hsp60, MEF2a and SRF   
To analyze protein expression of Cx43, Hsp60, MEF2a and SRF in transgenic mice, DRG 
samples were pulverized, homogenized in a buffer of pH 8.0 (50 mM Tris, 150 mM NaCl, 1% 
NP40, 0.5% Na-Deoxycholat, 0.1% SDS, 40 μl/ml Complete) and centrifuged at 4°C, 8000 g 
for 10 min. The supernatant was collected and the protein content was measured according to 
Lowry et al. Equal amounts of protein (40 μg per lane) were separated by Sodium dodecyl 
sulfate polyacrylamide gel electrophoresis. The gel was run for 85 min at a constant current of 
100 V and the proteins were transferred to a polyvinylidene difluoride membrane at 220 mA 
for 60 min. The membrane was blocked with 5% dried skimmed milk in Tris-buffered saline 
with 0.1% Tween for 2 h at room temperature and incubated with the primary antibodies 
(Cx43, ab11370, 1:10000; Hsp60, ab46798, 1:20000; MEF2a, ab32866, 1:1000; SRF, 
ab53147, 1:1000; abcam, Cambridge, UK) overnight at 4°C. The secondary antibody was 
applied for 2 h after washing with cold TBS-T three times for 10 min. The membrane was 
washed again in TBS-T and bound antibodies were visualized using the enhanced 
chemoluminescent detection method by a digital camera (cool snap HQ2; Photometrics
®
, 
Tuscon, AZ). Signals were quantified by densitometry (GelScan; BioSciTec GmbH, 
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Frankfurt/ Main, Germany) using glyceraldehyde 3-phosphate dehydrogenase (GAPDH, 
ab8245, 1:40000, abcam, Cambridge, UK) as a control protein to ensure equal loading of the 
gel.  
 
BDNF ELISA 
BDNF protein levels of DRG were analyzed using the BDNF Emax® ImmunoAssay System 
(Promega, Madison, Wisconsin). Protein isolation was performed as described above. 
According to the manufacturer’s protocol, ninety-six-well plates were coated with anti-BDNF 
monoclonal antibody and buffer (0.025M sodium bicarbonate and 0.025M sodium carbonate 
adjusted to pH 9.7) and incubated at 4 °C overnight. The plates were washed with TBS-T and 
incubated with 200 μl of Block and Sample buffer (BDNF Emax™ ImmunoAssay System, 
Promega, Madison, WI, USA) for 1 h at room temperature before samples were added. 
Briefly, 100 μl of each sample and BDNF standards were transferred to the ELISA plate, 
shaked for 2 h followed by incubation with anti-human BDNF polyclonal antibody and anti-
IgG antibody conjugated to horseradish peroxidase. The color reaction was stopped with 1 M 
HCl and the absorbance was measured at 450 nm. BDNF levels were calculated from the 
standard curve prepared for each plate and normalized to the concentration of total protein in 
each sample. The standard curves were linear within the range used (0–500 pg/ml). 
 
Statistics 
Results are expressed as mean ± SEM and analyzed by student’s t test or oneway-ANOVA 
using GraphPad Prism Software version 6 (San Diego California USA) or Partek Genomics 
Suite software (vers. 6.6; Partek, Inc.), respectively. The significance threshold was set to p < 
0.05.  
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Figure legends 
 
Figure 1: BDNF expression in adult Bdnf cKO mice at an early time point after BDNF 
gene deletion.  
Quantification of BDNF mRNA in (A) DRG, (B) sciatic nerve and (C) spinal cord with qRT-
PCR, presented as relative expression levels (n=9). ELISA measurements of BDNF in (D) 
DRG, (E) sciatic nerve and (F) spinal cord (n=5). White bars represent data from WT mice, 
while black bars represent data from BDNFAvCreERT2 mice 10 days after the last tamoxifen 
injection. Data are presented as mean±SEM. Statistical analysis was performed with unpaired 
t-test; ***p<0.001; **p<0.01.  
Figure 2: miR-1 is downregulated in DRG of adult Bdnf cKO mice at an early time point 
after BDNF gene deletion. (A) Expression of miR-1 and (B) miR-124a (control) in DRG 
were detected using qRT-PCR. Data are presented as normalized levels (n=9). White bars 
represent data from WT mice, while black bars represent data from BDNFAvCreERT2 mice 
10 days after the last tamoxifen injection. Data are presented as mean±SEM. Statistical 
analysis was performed with unpaired t-test; *p<0.05. 
Figure 3: Hsp60 and Cx43 expression in DRG of adult Bdnf cKO animals at an early 
time point after BDNF gene deletion (A) Hsp60 and (B) Cx43 protein expression in DRG 
were determined by Western blot analysis. Data are presented as normalized levels (n=8). 
White bars represent data from WT mice, while black bars represent data from 
BDNFAvCreERT2 mice 10 days after the last tamoxifen injection. Data are presented as 
mean±SEM. Statistical analysis was performed with unpaired t-test; *p<0.05. 
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Figure 4: BDNF expression in DRG of adult Bdnf cKO mice at a late time point after 
BDNF gene deletion. Quantification of BDNF mRNA in DRG with qRT-PCR, presented as 
normalized levels (n=5). White bars represent data from WT mice, while black bars represent 
data from BDNFAvCreERT2 mice 32 days after the last tamoxifen injection. Data are 
presented as mean±SEM. Statistical analysis was performed with unpaired t-test; *p<0.05. 
Figure 5: MiR-1 expression changes in DRG of adult Bdnf cKO mice at a late time point 
after BDNF gene deletion. Expression of miR-1 in DRG using qRT-PCR. Data are presented 
as normalized levels (n=5). White bars represent data from WT mice, while black bars 
represent data from Bdnf cKO mice 32 days after the last tamoxifen injection. Data are 
presented as mean±SEM. Statistical analysis was performed with unpaired t-test. 
Figure 6: Hsp60 and Cx43 expression in DRG of adult Bdnf cKO animals at a late time 
point after BDNF gene deletion. Hsp60 (A) and Cx43 (B) protein expression in DRG were 
determined by Western blot analyses. Data are presented as normalized levels (n=5). White 
bars represent data from WT mice, while black bars represent data from Bdnf cKO mice 32 
days after the last tamoxifen injection. Data are presented as mean±SEM. Statistical analysis 
was performed with unpaired t-test. 
Figure 7: MiRNA microarray in DRG of adult Bdnf cKO mice at a late time point after 
BDNF gene deletion. (A) Hierarchical clustering of differentially expressed microRNAs. 
167 miRNAs were significantly dysregulated in DRG of late targeted adult Bdnf cKO mice 
(p<0.05). Signal intensities (log2, normalized) are color coded:. Green denotes 
downregulation while red denotes upregulation relative to the median. Statistical analysis was 
performed using one-way-ANOVA. (B) 54 differentially expressed miRNAs in DRG of late 
targeted adult Bdnf cKO mice. The shown data required a minimum miRNA expression 
change of 20% compared to WT mice and are grouped by statistical significance (*p<0.05; 
**p<0.01). Statistical analysis was performed with one-way ANOVA. 
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Figure 8: Model of miR-1-associated effects in DRG-specific conditional BDNF-deficient 
mice. (A) miR-1 negatively regulates BDNF and the neuropathic pain-associated proteins 
Hsp60 and Cx43. Hypothesized positive regulatory loop from BDNF towards miR-1. (B) 
Hypothesized impairment of the positive feedback loop due to BDNF gene targeting. 
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Fig. 1 
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Fig. 2 
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Fig. 3 
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Fig. 4 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 28 
Fig. 5 
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Fig. 6 
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Fig. 7 
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Fig. 8 
 
  
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
 32 
Highlights 
· Transgenic deletion of Bdnf in DRG neurons leads to dysregulation of miR-1 
· This points to a feedback loop between BDNF protein and its targeting miR-1 
· miR-1 regulated proteins like Hsp60 are affected by this transient dysregulation 
· Moreover, expression levels of various other miRNAs may remain permanently 
altered 
· This might influence the phenotype after inducible Bdnf gene deletion 
